Novartis Gets FDA Nod for Tafinlar With Mekinist for Children

Novartis got FDA approval for Tafinlar (dabrafenib) with Mekinist (trametinib) for pediatric patients 1 year of age and older.

• Approval covers patients with low-grade glioma with a BRAF V600E mutation who require systemic therapy
• It’s the first FDA approval of a systemic therapy for the first-line treatment of pediatric patients with LGG with a BRAF V600E mutation

NOTE

• Novartis AG rose 2.0% to CHF76.99 as of last close
  • The average 12-month price target of CHF89.55 is 16.3% above the current price
  • 14 buys, 13 holds, 4 sells

To view the source of this information, click here

To contact the reporter ...